20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Guardant Health Inc (GH) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Palo Alto, United States with about 2,490 employees. Its market capitalization is roughly $24 billion. In the fiscal year ended 2025-12-31, GH reported $982M in revenue and ($416M) in net income.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Interactive charts & full statements → Open the GH valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.2B | $982M | $739M | $564M | $450M | $374M | $287M | $214M | $91M | $50M | $25M |
| Gross Profit | $770M | $633M | $449M | $337M | $293M | $251M | $194M | $144M | $47M | $18M | $3M |
| Gross Margin % | 65.1% | 64.5% | 60.8% | 59.7% | 65.2% | 67.1% | 67.7% | 67.0% | 52.3% | 36.6% | 12.4% |
| Operating Income (EBIT) | ($470M) | ($436M) | ($444M) | ($565M) | ($544M) | ($411M) | ($255M) | ($82M) | ($93M) | ($77M) | ($44M) |
| Operating Margin % | -39.7% | -44.4% | -60.0% | -100.1% | -121.1% | -110.0% | -88.9% | -38.4% | -102.5% | -153.7% | -173.7% |
| Net Income | ($453M) | ($416M) | ($436M) | ($479M) | ($655M) | ($406M) | ($254M) | ($76M) | ($85M) | ($83M) | ($46M) |
| Net Margin % | -38.3% | -42.4% | -59.1% | -85.0% | -145.6% | -108.6% | -88.5% | -35.3% | -93.8% | -167.0% | -182.7% |
| EBITDA | — | ($374M) | ($390M) | ($433M) | ($615M) | ($360M) | ($225M) | ($55M) | ($76M) | ($75M) | ($39M) |
| Earnings Per Share (EPS) | $-3.49 | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 | $-0.84 | $-1.00 | $-1.18 | $-3.49 |
| Shares Outstanding (M) | — | 125M | 123M | 112M | 102M | 101M | 98M | 91M | 85M | 71M | 13M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $335M | $302M | $281M | $265M | $232M | $203M | $202M | $191M | $177M |
| Gross Profit | $219M | $197M | $182M | $172M | $151M | $129M | $124M | $117M | $105M |
| Gross Margin % | 65.4% | 65.2% | 64.6% | 64.7% | 65.0% | 63.3% | 61.6% | 61.1% | 59.1% |
| Operating Income (EBIT) | ($129M) | ($121M) | ($121M) | ($99M) | ($106M) | ($111M) | ($126M) | ($117M) | ($101M) |
| Operating Margin % | -38.5% | -40.2% | -43.0% | -37.3% | -45.9% | -54.6% | -62.4% | -61.3% | -56.8% |
| Net Income | ($120M) | ($112M) | ($128M) | ($93M) | ($100M) | ($95M) | ($111M) | ($108M) | ($103M) |
| Net Margin % | -35.8% | -37.1% | -45.7% | -35.0% | -43.0% | -46.8% | -55.0% | -56.3% | -57.9% |
| EBITDA | — | ($101M) | ($119M) | ($82M) | ($89M) | ($84M) | ($99M) | ($96M) | ($91M) |
| Earnings Per Share (EPS) | $-0.90 | $-0.85 | $-1.00 | $-0.74 | $-0.80 | $-0.77 | $-0.90 | $-0.88 | $-0.84 |
| Shares Outstanding (M) | — | 131M | 129M | 125M | 124M | 124M | 124M | 123M | 122M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($173M) | ($185M) | ($240M) | ($325M) | ($309M) | ($209M) | ($104M) | ($47M) | ($72M) | ($72M) | ($37M) |
| Capital Expenditures (CapEx) | $56M | $48M | $35M | $20M | $77M | $75M | $54M | $21M | $20M | $9M | $2M |
| Free Cash Flow (FCF) | ($229M) | ($233M) | ($275M) | ($345M) | ($387M) | ($284M) | ($158M) | ($68M) | ($92M) | ($81M) | ($38M) |
| FCF Margin % | -19.4% | -23.7% | -37.2% | -61.3% | -86.1% | -76.0% | -55.1% | -31.9% | -101.9% | -162.9% | -152.4% |
| Dividends Paid | — | — | — | — | — | $18M | $7M | — | $3M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($58M) | ($66M) | ($14M) | ($35M) | ($60M) | ($63M) | ($65M) | ($51M) | ($94M) |
| Capital Expenditures (CapEx) | $12M | $6M | $28M | $10M | $6M | $4M | $19M | $4M | $5M |
| Free Cash Flow (FCF) | ($70M) | ($71M) | ($42M) | ($46M) | ($66M) | ($67M) | ($83M) | ($55M) | ($99M) |
| FCF Margin % | -20.9% | -23.6% | -14.9% | -17.3% | -28.4% | -33.0% | -41.3% | -28.9% | -55.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.9B | $2.0B | $1.5B | $1.8B | $1.6B | $2.2B | $2.3B | $963M | $587M | $343M | $117M |
| Cash & Cash Equivalents | $1.1B | $378M | $526M | $1.1B | $142M | $492M | $833M | $143M | $141M | $72M | $34M |
| Total Liabilities | $2.1B | $2.1B | $1.6B | $1.6B | $1.6B | $1.6B | $916M | $115M | $62M | $34M | $37M |
| Total Debt (Short + Long-Term) | $1.7B | $1.5B | $1.2B | $1.2B | $1.2B | $1.1B | $813M | $7M | $0M | $1M | $17M |
| Total Shareholders' Equity | ($223M) | ($99M) | ($140M) | $159M | $60M | $645M | $1.3B | $798M | $483M | $309M | $80M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GH viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms